New clinical trial on µsmin® Plus: efficacy for leg comfort and vein health

13 May 2021

Giellepi is pleased to announce the publication of a new clinical study on µsmin® Plus (Microsmin Plus), a diosmin preparation with enhanced bioavailability, titled “Efficacy of a Low-Dose Diosmin Therapy on Improving Symptoms and Quality of Life in Patients with Chronic Venous Disease: Randomized, Double-Blind, Placebo-Controlled Trial”.

Download here the technical paper to see the results! 

The results published in Nutrients further strengthen µsmin® Plus’ superiority in the diosmin marketplace showing dramatic improvements in leg circumference, quality of life (QOL), leg pain, and common symptoms associated with Chronic Venous Disease (CVD).

Veins are an important part of our body’s circulatory system as they carry blood back to the heart. Unfortunately, vein health is an area often overlooked by most people and can become more than just a cosmetic concern. As a result, the global burden of venous problems including varicose veins and chronic venous disease is increasing.

“We are delighted with the results of this study which revealed the ability of µsmin® Plus in quickly delivering leg vein health benefits at almost less than half dosage recommended with conventional micronized diosmin”, says Dr. Rosario Russo Scientific Officer at Giellepi. “The highly bioavailable formulation of µsmin® Plus along with these new findings will help our customers further differentiate and stand out in a marketplace dominated by micronized diosmin ingredients.” Read the full article.

μsmin® Plus is the only diosmin on the market providing up to 9X better absorption than standard micronized diosmin and proven efficacy at low-dose regimen.

Download here the technical paper of the clinical results of µsmin® Plus!

SUBSCRIBE TO OUR NEWSLETTER

Stay updated on news

* indicates required